CAJ | 학술논문

目的：观察茵栀黄口服液联合更昔洛韦对新生儿巨细胞病毒（CMV）肝炎的临床疗效。方法：随机将63例CMV肝炎患儿分为2组。2组均采用更昔洛韦注射液治疗，观察组加用茵栀黄口服液，每次1/2支，3次/d。2组均以2周为1个疗程。2组患者常规使用其他保肝药物。结果：丙氨酸转氨酶(ALT)、血清谷草氨转氨酶(AST)、总胆红素(TBIL)、肿瘤坏死因子(TNF-α)、干扰素(IFN-γ)等指标2组治疗后均改善（P＜0.05），2组治疗后比较差异显著（P＜0.05）。血巨细胞病毒抗体(CMV-IgM)转阴率观察组为42.4%（14/33），对照组为30%（9/30），2组比较无显著差异（P＞0.05）。尿巨细胞病毒DNA(CMV-DNA)转阴率观察组为66.7%（22/33），对照组为33.3%（10/30），2组比较差异显著（P＜0.05）。结论：茵栀黄口服液联合更昔洛韦治疗新生儿CMV肝炎临床疗效显著，CMV-DNA转阴率高。
목적：관찰인치황구복액연합경석락위대신생인거세포병독（CMV）간염적림상료효。방법：수궤장63례CMV간염환인분위2조。2조균채용경석락위주사액치료，관찰조가용인치황구복액，매차1/2지，3차/d。2조균이2주위1개료정。2조환자상규사용기타보간약물。결과：병안산전안매(ALT)、혈청곡초안전안매(AST)、총담홍소(TBIL)、종류배사인자(TNF-α)、간우소(IFN-γ)등지표2조치료후균개선（P＜0.05），2조치료후비교차이현저（P＜0.05）。혈거세포병독항체(CMV-IgM)전음솔관찰조위42.4%（14/33），대조조위30%（9/30），2조비교무현저차이（P＞0.05）。뇨거세포병독DNA(CMV-DNA)전음솔관찰조위66.7%（22/33），대조조위33.3%（10/30），2조비교차이현저（P＜0.05）。결론：인치황구복액연합경석락위치료신생인CMV간염림상료효현저，CMV-DNA전음솔고。
Objective: To investigate curative effects of YinZhiHuang oral liquid and ganciclovir in treating neonatal cytomegalovirus (CMV) hepatitis. Methods:All 63 patients were randomized into two groups. Both groups accepted the injection of ganciclovir, the observation group were also administered with YinZhiHuang oral liquid, half of one bottle, three times per day. Two weeks were one course of the treatment. The patients in both groups still took other drugs to protect the liver. Results:The indexes of ALT, AST, TBIL, TNF-α, IFN-γand others were im-proved after treating in both groups (P<0.05), the difference was significant (P<0.05). Blood CMV-IgM negative conversion rate of the observation group was 42.4%(14/33), higher than 30%of the control group (9/30), there was insignificant difference (P>0.05). Urinary CMV-DNA negative conversion rate of the observation group was 66.7%(22/33), superior to 33.3% of the control group (10/30), the difference was significant (P<0.05). Conclusion:YinZhiHuang oral liquid and ganciclovir are effective in treating neonatal CMV hepatitis with high CMV-DNA neg-ative conversion rate.